MRI-derived right ventricular ejection fraction demonstrated excellent repeatability and a large treatment effect size (Cohen's d 0.81) in PAH patients, supporting its use as a clinical endpoint.
Observational (n=42)
Are non-invasive end points (MRI, 6-minute walk test, NT-proBNP) repeatable and sensitive to change in patients with pulmonary arterial hypertension?
MRI-derived right ventricular ejection fraction is a highly repeatable and sensitive non-invasive endpoint for assessing treatment effects in PAH, outperforming the 6-minute walk test and NT-proBNP.
Estimación del efecto: Cohen's d 0.81
Abstract End points that are repeatable and sensitive to change are important in pulmonary arterial hypertension (PAH) for clinical practice and trials of new therapies. In 42 patients with PAH, test–retest repeatability was assessed using the intraclass correlation coefficient and treatment effect size using Cohen’s d statistic. Intraclass correlation coefficients demonstrated excellent repeatability for MRI, 6 min walk test and log to base 10 N-terminal pro-brain natriuretic peptide (log 10 NT-proBNP). The treatment effect size for MRI-derived right ventricular ejection fraction was large (Cohen’s d 0.81), whereas the effect size for the 6 min walk test (Cohen’s d 0.22) and log 10 NT-proBNP (Cohen’s d 0.20) were fair. This study supports further evaluation of MRI as a non-invasive end point for clinical assessment and PAH therapy trials. Trial registration number NCT03841344 .
Swift et al. (Thu,) conducted a observational in Pulmonary arterial hypertension (PAH) (n=42). Non-invasive endpoints (MRI, 6 min walk test, NT-proBNP) was evaluated on Test-retest repeatability and treatment effect size (Cohen's d 0.81). MRI-derived right ventricular ejection fraction demonstrated excellent repeatability and a large treatment effect size (Cohen's d 0.81) in PAH patients, supporting its use as a clinical endpoint.